What is Drik?
Drik operates as a specialized CRO based in Oklahoma, focusing on preclinical toxicology studies essential for drug development. The company offers a comprehensive suite of services, including in vitro testing and animal studies, designed to assess the safety of new compounds. Drik distinguishes itself through advanced methodologies such as 3D Organotypic slice cultures and a commitment to developing customized assays tailored to client needs. Their operational ethos emphasizes cost certainty and high-quality research, ensuring clients receive dedicated attention throughout their safety evaluation processes.
How much funding has Drik raised?
Drik has raised a total of $27K across 1 funding round:
Debt
$27K
Debt (2021): $27K with participation from PPP
Key Investors in Drik
PPP
Public-Private Partnership
What's next for Drik?
With significant Series B/C stage financing and substantial expansion capital, Drik is poised for accelerated growth. This investment is expected to bolster its capabilities in preclinical drug development and toxicology services. The company is likely to enhance its research infrastructure, expand its service offerings, and potentially increase its market reach within the pharmaceutical, cosmetic, and chemical industries. The focus on customized assay development and advanced methodologies suggests a strategic push towards higher-value contract research services, positioning Drik as a key partner for companies navigating complex regulatory pathways.
See full Drik company page
